Gene expression and pain

Details Gene expression and pain Gene expression and pain

2011-05-17

2011-05-17

Schultz, James (Doug) (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C536S024500, C435S006120, C435S325000, C435S375000

Reexamination Certificate

active

07943591

ABSTRACT:
The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.

REFERENCES:
patent: 5206152 (1993-04-01), Sukhatme
patent: 5683985 (1997-11-01), Chu et al.
patent: 6004813 (1999-12-01), Serlupi-Crescenzi et al.
patent: 6008048 (1999-12-01), Monia et al.
patent: 6022863 (2000-02-01), Peyman
patent: 6060310 (2000-05-01), Cho-Chung
patent: 6262033 (2001-07-01), Morishita et al.
patent: 6316190 (2001-11-01), Rein et al.
patent: 6333408 (2001-12-01), Motojima et al.
patent: 6410516 (2002-06-01), Baltimore et al.
patent: 6410721 (2002-06-01), Hunt et al.
patent: 6599741 (2003-07-01), Hecker et al.
patent: 6774118 (2004-08-01), Dzau et al.
patent: 6821956 (2004-11-01), Dzau et al.
patent: 6867289 (2005-03-01), Luxon et al.
patent: 6890909 (2005-05-01), Ono et al.
patent: 6969704 (2005-11-01), Pinsky et al.
patent: 7060690 (2006-06-01), Klem
patent: 7186556 (2007-03-01), Hecker et al.
patent: 2002/0192184 (2002-12-01), Carpentier
patent: 2003/0166555 (2003-09-01), Alberini et al.
patent: 2004/0048820 (2004-03-01), Hecker et al.
patent: 2004/0229833 (2004-11-01), Dzau et al.
patent: 2005/0192238 (2005-09-01), Hecker et al.
patent: 2006/0069055 (2006-03-01), Dajee et al.
patent: 2006/0116344 (2006-06-01), Morishita et al.
patent: 2006/0122134 (2006-06-01), Cattaruzza et al.
patent: 2006/0153847 (2006-07-01), Masuda
patent: 2006/0154886 (2006-07-01), Weihe et al.
patent: 2006/0166916 (2006-07-01), Mathison
patent: 2006/0189564 (2006-08-01), Burright et al.
patent: 2006/0293264 (2006-12-01), Grandis et al.
patent: 0572287 (1993-12-01), None
patent: 1281763 (2003-02-01), None
patent: 1298141 (2003-04-01), None
patent: 1357184 (2003-10-01), None
patent: 1690544 (2006-08-01), None
patent: 2005-336081 (2005-12-01), None
patent: 2005-0016361 (2005-02-01), None
patent: 96/29433 (1996-09-01), None
patent: 99/26634 (1999-06-01), None
patent: 02/29044 (2002-04-01), None
patent: 02/066071 (2002-08-01), None
patent: 02/070668 (2002-09-01), None
patent: 03/063799 (2003-08-01), None
patent: 2006/035434 (2006-04-01), None
Motojima et al., Sp1-like activity mediates angotensin-II-induced plasminogen-activator inhibitor type-1 (PAI-1) gene expression in mesangial cells. Biochem J. 349:435-441 (2000).
Lesniak et al., Binding and functional characteristics of two E-box motifs within the S100A6 (calcyclin) gene promoter. J Cell Biochem. Apr. 1;97(5):1017-24 (2006).
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration issued in corresponding international application No. PCT/US2008/063471, mailed Jan. 14, 2009.
Foti D et al., A nucleoprotein complex containing Sp1, C/EBPbeta, and HMGI-Y controls human insulin receptor gene transcription. Mol Cell Biol. 23(8):2720-32 (2003).
Sassa Y et al., Functional role of Egr-1 mediating VEGF-induced tissue factor expression in the retinal capillary endothelium. Graefes Arch Clin Exp Ophthalmol. 240(12):1003-10 (2002).
Xiang F et al., Egr-1 mediates Si0(2-driven transcription of membrane type I matrix metalloproteinase in macrophages. J Huazhong Univ Sci Technolog Med Sci. 27(1):13-6 (2007).
Ahn et al.; Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ Res. 90:1325-32 (2002).
Börner et al.; STAT6 transcription factor binding sites with mismatches within the canonical 5′-TTC . . . GAA-3′ motif involved in regulation of delta- and mu-opiod receptors. J Neurochem. 91(6):1493-500 (2004).
Buchwald et al.; Decoy oligodeoxynucleotide against activator protein-1 reduces neointimal proliferation after coronary angioplasty in hypercholesterolemic minipigs. JACC. 39:732-8 (2002).
Cattaruzza et al.; Mechanosensitive transcription factors involved in endotherlin B receptor expression. J Biol Chem. 276(40):36999-7003 (2001).
Chen et al.; Up-regulation of Egr1 by 1.25-dihydroxyvitamin D3 contributes to increased expression of p35 activator of cyclin-dependent kinase 5 and consequent onset of the terminal phase of HL60 cell differentiation. Cancer Res. 64(15):5425-33 (2004).
Cho et al., A genomic-scale view of the cAMP response element-enhancer decoy: a tumor target based genetic tool. PNAS. 99(24):15626-31 (2002).
Cho et al.; Potentiation of lipopolysaccharide-inducible cyclooxygenase 2 expression by C2-ceramide via c-Jun N-terminal kinase-mediated activation of CCAAT/enhancer binding protein in macrophages. MolPharmacol. 63(3):512-23 (2003).
D'Acquisto et al.; Local administration of transcription factor decoy oligonucleotides to nuclear factor-kB prevents carrageenin-induced inflammation in rat hind paw. Gene Ther. 7(20):1731-7 (2000).
Dash et al.; Sequestration of serum response factor in the hippocampimpairs long-term spatial memory. J Neuroch. 93:269-78 (2005).
Gao et al.; A single decoy oligodeoxynucleotides targeting multiple oncoproteins strong anticancer effects. Mol Pharmacol. 70(5):1621-9 (2006).
Grote et al.; Stretch-inducible expression of the angiogenic factor CCN1 in vascular smooth muscle cells is mediated by Egr-1. J Biol Chem. 279(53):55675-81 (2004).
Gupta AK and Kone BC; USF-1 and USF-2 trans-repress IL-1beta-induced iNOS transcription in mesangial cells. Am J Physiol Cell Physiol. 283:C1065-72 (2002).
Herdegen T and Leah JD; Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins, Brain Res Brain Res Rev. 28(3):370-490 (1998).
Igwe OJ; Modulation of peripheral inflammation in sensory ganglia by nuclear factor κB decoy oligodeoxynucleotide: involvement of SRC kinase pathway. Neurosci Lett. 381(1-2):114-9 (2005).
Ishibashi et al.; Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor. transforming growth factor b1. and tissue factor and also cell growth and invasion activities. Cancer Res. 60:6531-6 (2000).
Kamimura et al.; Platelet-derived growth factor induces tissue factor expression in vascular smooth muscle cells via activation of Egr-1. Hypertension. 44(6):944-51 (2004).
Kelkenberg et al.; CCAAT/enhancer-binding protein decoy oligodeoxynucleotide inhibition of macrophage-rich vascular lesion formation in hypercholesterolemic rabbits; Arterioscler Thromb Vasc Biol. 22:949-54 (2002).
Kohlstedt K et al.; Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension. 45:126-32 (2005).
Kraus et al.; The role of nuclear factor kappaB in tumor necrosis factor-regulated transcription of the human mu-opioid receptor gene. Mol Pharmacol. 64(4):876-84. Oct. 2003.
Lee et al.; Spinal NFKB activation induces COX2 upregulation and contributes to inflammatory pain hypersensitivity. Eur J Neurosci. 19:3375-81 (2004).
Leong et al.; Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. PNAS. 100(7):4138-43 (2003).
Lim et al.; Sequence-independent inhibition of RNA transcription by DNA dumbbells and other decoys. Nucl Acids Res. 25(3):575-581 (1997).
Ma et al.; Intrathecal injection of cAMP response element binding protein (CREB) antisense oligonucleotide attenuates tactile allodynia caused by partial sciatic nerve ligation. Brain Research. 988:97-104 (2003).
Mann et al.; Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre. randomised. controlled trial. The Lancet. 354:1493-8 (1999).
Morishita et al.; A gene therapy stategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. PNAS. 92:5855-9 (1995).
Ohtani et al; Inhibition of neointimal hyperplasia after balloon injury by cis-element ‘decoy’ of early growth response gene-1 in hypercholesterolemic rabbits. Gene Ther. 11(2):126-32 (2004).
Park e

Affiliated with

Also associated with

Rating

Gene expression and pain does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gene expression and pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene expression and pain will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2644842